tarextumab   Click here for help

GtoPdb Ligand ID: 8453

Synonyms: OMP-59R5
Compound class: Antibody
Comment: Tarextumab is fully human IgG2 monoclonal antibody targeting Notch receptors 2 and 3.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain of tarextumab reveals 100% match with sequences patented in US8226943 B2 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Tarextumab (OMP-59R5) was progressed to clinical trial for a selection of advanced solid tumours. In January 2015 the US FDA granted tarextumab orphan drug designation for the treatment of pancreatic cancer and small cell lung cancer. However, development appears to have been discontinued, likely due to a failure to show efficacy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tarextumab binds to Notch 2 and Notch 3 receptors, thereby prevenitng activation of the Notch signalling pathway. Notch pathway inhibition has anti-cancer effects.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01277146 A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors Phase 1 Interventional Mereo BioPharma 3
NCT00001693 Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers Phase 1 Interventional National Institutes of Health Clinical Center (CC) 2